Shigella sonnei, an intestinal pathogen, produces a characteristic form I cell surface antigen now known to be plasmid encoded. We considered that the GalE Salmonella typhi Ty2la oral vaccine strain, highly effective against typhoid, might be modified so as to be protective also against shigellosis due to S. sonnei. The plasmid responsible for form I antigen synthesis was therefore conjugally transferred to the galE S. typhi strain. Serological studies revealed that the derivative strain produces the form I antigen in addition to the normal S. typhi somatic antigens. Testing in mice demonstrated that the derivative form I galE S. typhi strain is protective against both S. sonnei and S. typhi challenges. These data suggest that the galE S. typhi Ty21a oral vaccine strain, which presumably stimulates the local immune system in the intestine, may also serve as a useful carrier for other antigenic determinants to protect against different intestinal infections.
Bacillary dysentery remains highly endemic in many areas of the world and still is a significant cause of illness in developed countries. In the United States, shigellosis occurs mainly in mental institutions, in prisons, on Indian reservations, and in inner cities. Approximately twothirds of the cases are caused by Shigella sonnei.
Because shigellosis is an infection limited to the superficial layer of the colonic mucosa, it is not surprising that attempts to immunize humans or other primates with killed vaccines or even living virulent organisms, administered by the parenteral route, have not been successful (6, 9, 10) . On the other hand, attenuated Shigella strains given by the oral route have been effective in protecting against the disease under both laboratory and field conditions (4, 12, 15) . It has been suggested that the local intestinal immune response which is induced by the living oral vaccines inhibits invasion of intestinal epithelial cells by the pathogen (12) . This immunity has been associated with the type-specific somatic antigen of the vaccine strain (5, 12) . These attenuated shigella vaccines, however, have not been put into widespread use because of difficulties in isolating safe, genetically stable strains that require only a limited number of doses to induce resistance.
Unlike shigella, typhoid bacilli cause a systemic infection after penetration of the intestinal mucosa, and parenteral vaccines have been shown to be effective against this infection (1). These parenteral vaccines do, however, elicit significant side effects which include fever, malaise, headache, and localized reactions at the site of inoculation. Recently, Germanier and Furer (7) have reported on the isolation and characterization of a galactose epimeraseless (galE) mutant of Salmonella typhi for use as a living attenuated oral typhoid vaccine. This vaccine strain has been tested in volunteers (8) and in an extensive field trial in Egypt (15) and has been shown to be safe and highly effective. Furthermore, it does not produce the above-mentioned side effects.
S. sonnei organisms produce a characteristic cell surface antigen, termed form I, which has altruonic acid as a component of its 0-specific side chain. Recently, we and others have demonstrated that the form I antigen is encoded by a large nonconjugative plasmid (11, 14) . By utilizing a plasmid mobilizing system, we have been able to transfer the form I antigen-synthesizing genes to different bacterial genera, including Salmonella (11 Fig. 1 , the recipient S. typhi Ty2la strain contained no large plasmids. However, both the donor and transconjugant strains harbored two large plasmid species which correspond to the independent F' lac(Ts):::Tn3 (-80-megadalton) and the form I ('120-megadalton) plasmids. Thus, it appears that form I antigen synthesis in the S. typhi transconjugant strain 5076-1C is due to the presence of the form I plasmid.
Serological characterization of form I galE S. typhi derivative strain 5076-1C. As shown in Table 2 5054-6-1 reacted in S. typhi antiserum.
In further studies, adsorption of S. sonnei form I-specific antiserum with cells of the S. typhi form I strain 5076-1C reduced the titer against S. sonnei form I strain 53G to <1:80. Similarly, adsorption of S. typhi 643W antiserum with the S. typhi form I 5076-1C cells lowered the titer against cells of S. typhi 643W from 1: 1,600 to 1:160. Thus, the S. typhi galE form I strain 5076-1C produces both the normal S. typhi somatic antigens and the S. sonnei form I antigen.
Galactose-induced sensitivity to lysis. S. typhi strain Ty21a contains a galE mutation that, after galactose uptake and the intracellular accumulation of galactose-1-phosphate and uridine diphosphate-glactose, results in cell lysis. The growth patterns of S. typhi strains Ty2la and 5076-1C, when grown in BHI broth in the presence or absence of 0.1% galactose, are shown in Fig. 2 . Both strains are similarly inhibited by the presence of galactose in the medium, relative to the control Gal' S. typhi strain Ty2, which is not inhibited by galactose.
Persistence in mouse tissue of parental and transconjugant galE S. typhi strains. Cells of S. typhi Ty2la and the transconjugant form I strain 5076-1C were each injected intraperitoneally into separate groups of 18 mice as described above. Three animals were sacrificed at intervals of up to 15 days postinoculation, and the spleens were checked for the presence of bacteria as described in the assay protocol. All animals harbored viable cells of either organism when the animals were sacrificed after 1 to 3 days postinoculation. However, cultures of subsequently sacrificed animals were uniformly negative.
To test the safety of slightly larger doses of these vaccine strains, groups of five mice were injected intraperitoneally with 10' cells of either S. typhi Ty2la or the derivative strain 5076-1C suspended in hog gastric mucin. All animals survived during the 1-week observation period. Therefore, both the parental and transconjugant form I galE S. typhi strains behaved as expected, and viable cells did not persist in infected mice for longer than 3 to 6 days.
Mouse protection studies. Viable cells of S. typhi Ty2la, S. sonnei 53G form I, and S. typhi galE form I strain 5076-1C as well as the standard acetone-killed and dried S. typhi Ty2 cells were used to immunize mice by either the intraperitoneal or subcutaneous route. Control mice received inocula of saline. All mice were challenged 4 weeks postimmunization, and deaths were recorded after 72 h. The results of these studies are summarized in Table 3 . Each of the monovalent vaccines protected against homologous challenge but not against heterologous challenge. In contrast, the form I S. typhi Ty2la derivative strain 5076-1C protected against challenge with either S. typhi or S. sonnei.
DISCUSSION
The galE mutant S. typhi strain Ty2la has been shown to be a safe and effective oral vaccine against typhoid fever in humans (8, 15 The inability of the galE S. typhi Ty2la or its derivative strain 5076-1C to cause disease is due to growth inhibition and cell lysis which follows the uptake of galactose and the intracellular accumulation of galactose-i-phosphate and uridine diphosphate-galactose. Despite lacking the Vi antigen (8, 15) , a cell surface component generally found in natural S. typhi isolates, these strains still are effective oral immunogens against typhoid fever. Although the precise mechanism by which immunity is induced by oral vaccines is unknown, it is likely that antigen must stimulate antibody-forming cells in the lamina propria to confer immunity. The question of whether or not protective antigen(s) is absorbed by the epithelium or is transported across the epithelium by intact bacterial cells remains unanswered. Furthermore, it is not known if immunity is manifest on the mucosal surface to block bacterial penetration or in the tissues to limit multiplication should penetration occur.
These preliminary studies indicate that the form I galE S. typhi strain 5076-1C is an effective immunizing agent in mice for protection against S. typhi and S. sonnei. Since this derivative strain maintains its sensitivity to galactose, it should be safe for use in humans. The major concern now is whether or not this strain will act INFECT. IMMUN. as an effective vaccine in the human intestine. Since there are well-defined foci of S. sonnei disease in the United States, it should be quite feasible to answer this question. Considerable impetus for using the S. typhi galE mutant as a carrier strain for other potentially protective antigenic determinants (e.g., toxin or toxoid genes, colonization antigens, and capsular antigens) will be provided should the Ty2la form I derivative strain prove effective.
